We are live on
!
Find out more
HVC
Healthcare Value Capital Portfolio holdings
AUM
$50.7M
Turnover
28.57%
1-Year Est. Return
24.72%
This Fund
S&P 500
This Quarter
Est. Return
-0.42%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$58.5M
AUM Growth
-$34.9M
(-37%)
Cap. Flow
-$13.5M
Cap. Flow
% of AUM
-23.16%
Top 10 Holdings %
Top 10 Hldgs %
85.17%
Holding
24
New
4
Increased
–
Reduced
3
Closed
5
Avg Time Held Equity + Options
0.9
years
Top 10 Avg Time Held Equity + Options
0.8
years
Top 20 Avg Time Held Equity + Options
0.7
years
Avg Time Held Equity only
1.4
years
Top 10 Avg Time Held Equity only
1
year
Top 20 Avg Time Held Equity only
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Standard BioTools
LAB
|
+$1.74M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ANI Pharmaceuticals
ANIP
|
+$9.09M |
| 2 |
Amgen
AMGN
|
+$3.65M |
| 3 |
ARLZ
Aralez Pharmaceuticals Inc.
ARLZ
|
+$2.54M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 73.69% |
| 2 | Miscellaneous | 26.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
NVLN
1
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| $8.93M | 15.27% |
831,440
| – | – |
2016 Q4
1 quarter
|
|
2
Pfizer
PFE
$169B
| $8.55M | 14.63% |
263,500
| – | – |
2014 Q1
12 quarters
|
|
3
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$806B
| $5.89M | 10.08% |
25,000
-75,000
| -75% | -$17.4M |
2016 Q4
1 quarter
|
|
4
Gilead Sciences
GILD
$194B
| $5.09M | 8.71% |
75,000
| – | – |
2016 Q3
2 quarters
|
|
5
DELISTED
Assertio
ASRT
| $4.39M | 7.51% |
5,833
| – | – |
2015 Q4
5 quarters
|
|
|
AMRI
6
DELISTED
Albany Molecular Research Inc
AMRI
| $4.24M | 7.26% |
302,400
| – | – |
2014 Q1
12 quarters
|
|
|
7
CALL
Gilead Sciences
GILD
$194B
| $4.08M | 6.97% |
60,000
| – | – |
2016 Q3
2 quarters
|
|
|
AGN
8
DELISTED
Allergan plc
AGN
| $3.58M | 6.13% |
15,000
| – | – |
2016 Q4
1 quarter
|
|
|
IPXL
9
CALL
DELISTED
Impax Laboratories, Inc.
IPXL
| $2.53M | 4.33% |
+200,000
| New | +$2.42M |
2017 Q1
0 quarters
|
|
10
Artivion
AORT
$1.06B
| $2.5M | 4.27% |
150,000
| – | – |
2014 Q3
10 quarters
|
|
11
Teva Pharmaceutical Industries Limited
TEVA
$48.4B
| $2.41M | 4.12% |
75,000
| – | – |
2016 Q4
1 quarter
|
|
|
12
Standard BioTools
LAB
$247M
| $1.56M | 2.68% |
+275,000
| New | +$1.74M |
2017 Q1
0 quarters
|
|
13
Amarin Corp
AMRN
$239M
| $1.44M | 2.46% |
22,500
| – | – |
2016 Q3
2 quarters
|
|
|
14
CALL
DELISTED
Assertio
ASRT
| $1.25M | 2.15% |
1,667
-2,500
| -60% | -$2.53M |
2016 Q4
1 quarter
|
|
15
CALL
ProShares UltraShort NASDAQ Biotechnology
BIS
$2M
| $695K | 1.19% |
3,125
-3,125
| -50% | -$737K |
2016 Q4
1 quarter
|
|
|
IMMU
16
CALL
DELISTED
Immunomedics Inc
IMMU
| $647K | 1.11% |
+100,000
| New | +$507K |
2017 Q1
0 quarters
|
|
|
ZGNX
17
DELISTED
Zogenix, Inc.
ZGNX
| $346K | 0.59% |
31,850
| – | – |
2015 Q1
8 quarters
|
|
|
18
CALL
Standard BioTools
LAB
$247M
| $285K | 0.49% |
+50,000
| New | +$317K |
2017 Q1
0 quarters
|
|
|
FCSC
19
DELISTED
Fibrocell Science Inc.
FCSC
| $32K | 0.05% |
3,185
| – | – |
2014 Q1
12 quarters
|
|
|
20
Amgen
AMGN
$234B
| – | – |
-25,000
| Closed | -$3.65M | – |
|
|
21
ANI Pharmaceuticals
ANIP
$1.66B
| – | – |
-150,000
| Closed | -$9.09M | – |
|
22
CALL
ProShares VIX Short-Term Futures ETF
VIXY
$241M
| – | – |
-234
| Closed | -$1.59M | – |
|
23
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| – | – |
-4,286
| Closed | -$543K | – |
|
|
ARLZ
24
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
| – | – |
-575,000
| Closed | -$2.54M | – |
|
Similar funds
C
CC
FCOI
FCOI
BI
KC
SCIM
MCP
Healthcare Value Capital's Q1 2017 Portfolio in Review
As of Q1 2017, Healthcare Value Capital held 24 positions worth $58.5M, down 37% from $93.3M the previous quarter. Its ten largest holdings account for 85% of the portfolio.
Healthcare Value Capital withdrew a net $13.5M in Q1 2017, closing 5 positions and reducing 3 holdings. Its most notable exit was ANI Pharmaceuticals, an estimated $9.09M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 62% a quarter earlier, followed by Miscellaneous.
Against the trend, Healthcare Value Capital opened a new position in Standard BioTools worth $1.56M.
- Healthcare Value Capital's largest Q1 2017 buy was Standard BioTools: 275,000 shares worth $1.56M.
- Healthcare Value Capital fully exited ANI Pharmaceuticals in Q1 2017, selling an estimated $9.09M.
- Healthcare Value Capital's ten largest holdings make up 85% of its $58.5M portfolio in Q1 2017.
- Healthcare Value Capital opened 4 new positions and closed 5 in Q1 2017.
- Healthcare Value Capital's portfolio value fell 37% quarter-over-quarter to $58.5M.
Based on Healthcare Value Capital's 13F filing for Q1 2017, filed 12 May 2017.